CompletedNCT00485407
Increasing atomoxetine for ADHD symptoms that remain after treatment
About this title
Read the official source — NCT00485407Medication studyAges 6–16United States + Canada
Understand this study
Who was this study for?
Listed age limits: 6 years to 16 years.
- Listed locations
- Scottsdale and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 377
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT00485407
- Official title
Show the full official title
Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale, United States · Vancouver, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 16 years.
